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Mouse  bone  marrow  cells  differentiate  in  vitro  into  a  relatively  homogeneous 
population  of  mast  cells  when  cultured  in  the  presence  of  conditioned  medium 
obtained  from  concanavalin  A-stimulated splenocytes  (1-3).  These  bone  marrow- 
derived mast  cells are  similar to  mouse  and  rat  serosal  mast  cells in  terms  of the 
histologic staining of their intracellular granules (1-3); the presence of I-5 ×  105 IgE 
Fc cell surface receptors  (1, 4);  and their overall ultrastructural morphology, which 
includes prominent granules, an oval nucleus, and extensive microvilli (3, 5, 6). There 
are,  however,  a  number  of criteria that  distinguish  cultured  bone  marrow-derived 
mast cells from mouse and rat serosal mast cells. Morphologically, the granules of the 
bone marrow-derived mast cells possess less electron-dense material (3, 5, 6) and only 
about one-tenth as much histamine as mouse and rat serosal mast cells (1, 5-8). The 
rate of proteoglycan synthesis in the bone marrow-derived mast  cell, as assessed by 
[35S]sulfate incorporation, is two- to sevenfold higher than  that of serosal mast cells. 
In addition, >90% of the proteoglycan synthesized possesses covalently bound chon- 
droitin sulfate E  glycosaminoglycans rather than heparin glycosaminoglycans (9,  10). 
Upon stimulation with the calcium ionophore A23187, mouse bone marrow-derived 
mast  cells release an  average of 90  ng of 5(S),  6(R)-5-hydroxy-6-S-glutathionyl-7,9- 
tram', 1 1,14-cis-eicosatetraenoic  acid (leukotriene C4, LTC4) 1/106 ceils and only 5.7 ng 
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of prostaglandin D2 (PGD2)/10 ~ cells (11). In contrast, under comparable conditions, 
rat serosal mast  cells release an  average of 50  ng of PGDJ106  cells and <0.7  ng of 
LTC4/106  cells  (11,  12).  Because  the  cultured  bone  marrow-derived  mast  cells 
synthesize a  different proteoglycan and  metabolize arachidonic  acid  to  a  different 
predominant  product,  it  is considered likely that  they  represent  a  subclass of mast 
cells  (9,  11)  rather  than  a  different  stage  of  development  caused  by  the  culture 
conditions for their differentiation. 
Activation of the IgE-bearing bone marrow-derived mast cells with anti-IgE results 
in the accumulation of the intracellular granules in channels that extend to the cell 
surface (5)  and in the exocytosis of the granular contents,  resulting in a  net percent 
release of histamine. Specific antigen-induced release of chondroitin sulfate E proteo- 
glycan and LTC4, as well as the conventional secretory granule markers fl-hexosamin- 
idase and  histamine  from  cultured  mast  cells sensitized with  monoclonal  IgE, now 
establish that all of these molecules are derived from bone marrow-differentiated mast 
cells. 
Materials and  Methods 
Culture of Mouse Bone Marrow-derived  Mast Cells.  Bone marrow cells, obtained from femurs of 
2-mo-old male BALB/c mice (The Jackson Laboratory, Bar Harbor, ME), were cultured for 14 
d at 37°C and at a starting density of 0.1 X 106 cells/ml in 50% RPMI 1640 supplemented with 
10% fetal calf serum, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml penicillin, 
100 U/ml streptomycin, and 50 #M 2-mercaptoethanol (Grand Island Biological Co., Grand 
Island,  NY),  pH  7.2  (enriched  medium),  and  50%  conditioned  medium  (1).  Conditioned 
medium was obtained from the co-culture of C57BL/6J and C3H mouse spleen cells (1 ×  10P/ 
ml) for 2 d in enriched medium containing 2 ~g/ml concanavalin A (Sigma Chemical Co., St. 
Louis, MO). After being in culture for 14 d  in a humidified atmosphere containing 5% CO2, 
the cells were stained with  toluidine blue at  pH  3.5.  Approximately 98%  of the cells were 
identified as mast cells by the presence of metachromatic granules. Less than 3% of the cells in 
these bone marrow-differentiated mast cell cultures ingested opsonized zymosan particles when 
incubated for 1 h at 37°C in Tyrode's buffer at a zymosan concentration of 1,600 p~g/106 cells 
and assessed after staining with Giemsa by light microscopy. 
Antigen-induced, IgE-mediated Release  of  Preformed  Mediators and of  Sulfidopeptide Leukotrienes.  Bone 
marrow-derived mast cells (1 ×  10~), in 0.2 ml of Tyrode's buffer containing 0.32 mM Ca  2÷, 0.2 
mM Mg  2+, and 0.5% gelatin (modified Tyrode's buffer), were sensitized by incubation for 1 h 
at 37°C with 0.1-10/~g of mouse monoclonal IgE directed against dinitrophenyl-bovine serum 
albumin (DNP-BSA) (13). Sensitized cells were washed with 2 ml of modified Tyrode's buffer, 
sedimented at  400 g  at  room  temperature,  and  suspended  in 0.5  ml  of prewarmed  (37°C) 
modified  Tyrode's  buffer  containing  0.8-500  ng  of  DNP-BSA  (18  mol  DNP/mol  BSA). 
Reactions were terminated by the addition of EDTA to give a final concentration of 2 mM and 
by sedimentation at 400 g for 5 min at room temperature. The supernatants were collected, and 
the cell pellets were suspended in  1 ml of 10 mM Tris-HC[, l  M  NaCI, pH 7.4, and sonicated 
at 4°C with a Branson sonifier (Branson Sonic Power Co., Danbury, CT; setting 3, 50% pulse 
cycle, 10 pulses). All experiments were carried out  in duplicate and included sensitized cells 
that were not incubated with antigen. Both the supernatants and the disrupted cell pellets were 
assayed for their content of various mediators, as described below. In certain experiments, the 
cell pellets were washed with 0.5  mI of 10  mM Tris-HCI and  1.5  M  NaCI, pH  7.4,  before 
sonication in order to solubilize any granule-bound enzymes and proteoglycans that were still 
cell associated (7). 
Cell viability was assessed by exclusion of Trypan  blue and  by the  measurement  of the 
release of cytosol lactate dehydrogenase (7). Histamine was measured by radioenzymatic assay 
(14) with 3H-labeled histamine,  methyl  14C-labeled  S-adenosyl-L-methionine (New  England 
Nuclear,  Boston,  MA)  and  rat  kidney histamine  methyltransferase. ~-ttexosaminidase was 
assayed by hydrolysis  ofp-nitrophenyl-B-D-2-acetamido-2-deoxyglucopyranoside  (Sigma Chem- 
ical Co.);  1 U  of enzyme cleaves 1 p.mol of substrate/h at 37°C  (15,  16). RAZIN ET AL.  191 
For quantitation of chondroitin sulfate E proteoglycan, bone marrow-derived mast cells (1 
×  107) were preincubated for 4 h at 37°C in 10 ml of enriched medium containing 50-100/tCi 
[3SS]sulfate/ml (New England Nuclear Corp). Radiolabeled mast cells were sedimented at 400 
g  for 5  min at room temperature and washed with enriched medium. The cells  were then 
sensitized with monoclonal IgE and challenged with DNP-BSA under the same experimental 
conditions as for unlabeled cells. After separation of the supernatant, intracellular 3~S-labeled 
proteoglycans were liberated at  4°C by the addition of 0.1  ml of a  solution containing 1% 
Zwittergent 3-12 detergent (Calbiochem-Behring  Corp., La Jolla, CA), 0.1 M 6-aminohexanoic 
acid, 0.1 M sodium EDTA, 5 mM benzamidine HC1, 1 mM sodium iodoacetamide, and 0.1 M 
sodium acetate,  pH  6.0,  followed  30-60 s later by the addition of 1 ml of 4  M  guanidine 
hydrochloride containing the same protease inhibitors (9). The 35S-labeled  macromolecules 
released  and  those  remaining cell  associated  were  both  quantitated  by  measurement  of 
radioactivity with a Searle Beta Counter (model 6880; Searle Analytic, Des Plaines, IL). 
The net percentages of release  of histamine,/~-hexosaminidase,  and SSS-labeled chondroitin 
sulfate E proteoglycan were calculated by the following formula: net percent release =  [S -- 
Scontrol]/[(S +  P) -  S~ontro~] ×  100, where S is the mediator content of supernatant of stimulated 
cells, P is the mediator content of pellet of stimulated cells, and Scontrol is the mediator content 
of supernatant of unstimulated cells. 
Generation  of the sulfidopeptide leukotrienes  was quantitated with radioimmunoassay  (RIA). 
The supernatants were diluted to 100 pl with 10 mM Tris-HCl, 0.15 M NaCI, and 0.1% gelatin, 
pH  7.3 (Isogel buffer); mixed with 50/d of buffer containing 5,000-7,000 cpm of 3H-labeled 
LTC4 (New  England Nuclear) and  100 #1 of class-specific  rabbit immune plasma (17);  and 
incubated for 1 h at 37°C. 3H-labeled LTC4 bound to the rabbit antibodies was precipitated 
by an overnight incubation at 4°C with 200/tl of goat anti-rabbit IgG. The precipitates were 
pelleted by centrifugation, solubilized in 0.1  N  NaOH,  and counted.  Synthetic LTC4 was 
detectable on the linear portion of a net radioligand binding inhibition  curve over a dose range 
from 0.1  to  1.0 ng (17). Because unstimulated cells did not generate immunoreactive leuko- 
trienes, the antigen-induced  release of leukotrienes is expressed as nanograms of product released 
into the supernatant per 10  ° cells. 
For quantitation of PGDz, supernatant diluted to 100 #1 in Isogel buffer was mixed with 50 
#1 of buffer containing 6,000 cpm of 3H-labeled PGD2  (New England Nuclear) and 100/tl of 
rabbit anti-PGD2 immune plasma for  1 h at 37°C. Normal rabbit plasma (100 pl)  and goat 
anti-rabbit IgG antiserum (200 pl)  were successively  added,  and samples were precipitated 
overnight at 4°C and centrifuged. The pellets were resolubilized in 0.1 N NaOH and counted. 
Synthetic PGDz was detectable on the linear portion of a net radioligand binding inhibition 
curve over a dose range from 0.1 to 2.0 ng (17). Antigen-induced  release of PGDe is expressed 
as nanograms of product released into the supernatant per 106 cells; release from unstimulated 
cells was not measurable. 
Characterization of Released Chemical Mediators.  The radiolabeled proteoglycans released into 
the medium and those remaining associated with the cells were characterized by gel filtration 
chromatography  on  Sepharose  CL-4B  and,  after  purification by  cesium  chloride  density 
gradient sedimentation, by the disaccharide content of their bound glycosaminoglycans (9). 
The  Sepharose  CL-4B  column  (0.6  ×  120  cm)  was  equilibrated and  eluted  with  a 4-M 
guanidine HCI solution containing  50 pg/ml of pig mucosa heparin glycosaminoglycan (Sigma 
Chemical Co.), 0.1 M sodium sulfate, and 0.1 M Tris-HC1, pH 7.5, at a flow rate of 1.5 ml/h. 
Samples of each  0.5-ml fraction were  analyzed for  radioactivity. Rat  mast cell  35S-labeled 
proteoglycan, rat  mast  cell  asS-labeled  glycosaminoglycan, pig dermatan sulfate, and  [35S]- 
sulfate were used as reference standards (9). 
The  35S-labeled  proteoglycans  that  were  purified  by  cesium  chloride  density  gradient 
centrifugation (9) were incubated for 1 h with 0.2 U ofchondroitinase ABC in 100/~1 Tris-HCt 
buffer (50 mM Tris-HC1, 50 mM NaCI, 35 mM sodium acetate, pH 8.0) containing  0.05% BSA 
(Sigma Chemical Co.)  and  100 #g of both chondroitin sulfate A and chondroitin sulfate C 
(Miles  Laboratories, Inc., Elkhart, IN) carriers. The reaction products were characterized by 
their mobility relative to disulfated and monosulfated disaccharide standards during ascending 
thin-layer chromatography on precoated cellulose acetate plates (EM Laboratory, Inc., Elms- 
ford,  NY)  (9,  18). The standards were:  2-acetamido-2-deoxy-3-O-(,8-I)-gluco-4-enepyranosylu- 192  BONE MARROW-DERIVED MAST CELL MEDIATORS 
tonic acid)-4-O-sulfo-n-galactose (ADi-4S);  2-acetamido-2-deoxy-3-O-(fl-D-gluco-4-enepyrano- 
syluronic acid)-6-O-sulfo-D-galactose  (ADi-6S);  2-acetamido-2-deoxy-3-O-(fl-D-gluco-4-enepyr- 
anosyluronic acid)-4-6-di-O-sulfo-D-galactose  (ADi-diSg);  2-acetamido-2-deoxy-3-O-(2-O-sulfo- 
/~-D-gluco-4-enepyranosyluronic acid)-6-O-sulfo-D-galactose  (ADi-diSD);  and  2-acetamido-2- 
deoxy-3-O-(fl-D-gluco-4-enepyranosyluronic  acid)-D-galactose  (ADi-OS).  Carrier disaccharides 
were visualized under ultraviolet light. [35S]Sulfate-labeled digestion products were localized by 
autoradiography with XR-5 x-ray film (Eastman Kodak Co., Rochester, NY) and quantitated 
by fl-scintillation  counting after elution with 1 ml of 0.5 M  HC1 for 2 h at 55°C. 
The bioassay of sulfidopeptide leukotrienes was performed on guinea pig ileum strips; a 
contraction amplitude of one SRS-A unit was defined as equal to that elicited by 5 ng/ml of 
histamine (19). Before their introduction onto reverse-phase high-performance liquid chroma- 
tography (RP-HPLC), the supernatants were mixed with 4 vol of ethanol for 30 rain at 4°C, 
centrifuged at 1,500  g for 10 min at 4°C to remove precipitated proteins, evaporated to dryness, 
and redissolved  in methanol:water (1:1). The leukotrienes were resolved by RP-HPLC with an 
isocratic solvent of methanol:water:acetic acid (65:34.9:0.1,  pH 5.6) at a flow rate of 1 ml/min 
(17). 1-ml samples were collected for 45 min with on-line monitoring of absorbance at 280 nm. 
Fractions were evaporated to dryness and redissolved in 0.5 ml Isogel buffer for measurement 
of biological activity and immunoreactivity. Synthetic LTC4, LTD4, and LTE4 (17) standards 
eluted with retention times of 15.4 +  0.5, 22.3 ±  0.7, and 28.2 ±  0.6 min (mean +  SEM, n = 
3), respectively,  with >85% recovery  for each compound (11, 20). 
Results 
Exocytosis of Granule Contents and Generation of Leukotrienes.  The bone marrow-derived 
mast cells, sensitized with monoclonal mouse IgE over a  dose range of 0.1  10/tg/106 
cells and then challenged for  10 rain with 20 ng of DNP-BSA, released fl-hexosamin- 
idase, histamine, and sulfidopeptide leukotrienes in a  dose-dependent relationship to 
the sensitizing concentration of IgE (Fig.  1). The plateau for the net percent release 
of  fl-hexosaminidase  and  histamine  and  that  for  the  release  of  immunoreactive 
sulfidopeptide leukotrienes occurred at the same sensitizing dose, 5 #g of IgE/106 cells. 
In two consecutive experiments in which cells sensitized with  10 btg IgE were washed 
three  times in Tyrode's buffer and then challenged with optimal antigen dose,  the 
washing step  increased antigen-induced release of leukotrienes by an average of 29 
±  5%  (mean ±  SEM). 
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FIG.  1.  Net percent antigen-induced release of fl-hexosaminidase (O) and of histamine (Q), and 
net release of sulfidopeptide leukotrienes (&) from bone marrow-derived mast cells sensitized with 
incremental concentrations of mouse monoclonal anti-DNP IgE. Results are expressed as mean + 
SEM of three experiments. Unstimulated cells released 10 -  2% offl-hexosaminidase and 10 + 3% 
of histamines, while failing to generate detectable leukotrienes. RAZIN  ET  AL.  193 
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Fic.  2.  DNP-BSA antigen dose-dependent net percent release of,B-hexosaminidase (0) and [35S]- 
proteoglycans  (O),  and  release of sulfidopeptide  leukotrienes  (&)  from sensitized bone  marrow- 
derived mast cells. Separate samples were radiolabeled for 4 h and washed before being assessed for 
antigen-induced release of aSS-labeled proteoglycans. Results are expressed as the mean +  SEM of 
three experiments for fl-hexosaminidase and  leukotrienes and  of six experiments for asS-labeled 
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FIo.  3.  Kinetics of antigen-induced net percent release of/~-hexosaminidase (0)  and asS-labeled 
proteoglycans  (O),  and  release of sulfidopeptide leukotrienes  (A)  from sensitized bone  marrow- 
derived mast cells. The release of fl-hexosaminidase and of [~S]proteoglycans from unstimulated 
cells was I0 and 9%, respectively, at 5 min and did not increase with longer incubations. 
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Because bone marrow-derived mast cells were to be routinely sensitized with  10 ~tg 
of IgE, the dose of DNP-BSA was varied from 0.8 to 500 ng/106 cells to determine the 
optimal dose for mediator release (Fig. 2). The net percent release of//-hexosaminidase 
and the release of immunoreactive sulfidopeptide leukotrienes reached their plateau 
values with 20 ng of DNP-BSA.  In separate experiments, the net  percent  release of 
asS-labeled proteoglycan reached a plateau at the same antigen concentration. 
The  kinetics  of the  release  of fl-hexosaminidase,  immunoreactive  sulfidopeptide 
leukotrienes, and asS-labeled proteoglycan were examined with three duplicate sets of 
1 ×  106 cells sensitized with  10 ~g of IgE and challenged with 20 ng DNP-BSA for 1- 
30 min (Fig. 3). The net percent release of fl-hexosaminidase and asS-labeled proteo- 
glycans and the release of sulfidopeptide leukotrienes had similar time courses, which 
reached plateaus 5 min after challenge. Washing radiolabeled mast cells with  1.5  M 
NaC1 in  10 mM Tris HCI after challenge did not increase the net percent release of 
asS-labeled proteoglycan. 
In two experiments with bone marrow-derived mast cells sensitized with 10/~g IgE/ 
106 cells and challenged with 20 ng DNP-BSA for 5 min at 37°C, the average release 
of PGD2 was <0.5 ng as compared with 26 ng of sulfidopeptide leukotrienes. Increasing 
the time period of antigen challenge did not result in further PGD2 release. 
When  the  data  for  the  net  pe~'cent release  of histamine  and fl-hexosaminidase, 
obtained from cells sensitized witl~ incremental doses of IgE (Fig.  1), were compared 
by linear regression analysis (21,225,  a correlation coefficient (r) of 0.91  (n =  10, P < 
0.01)  was obtained. A similar comparative analysis, examining the relationship of the 
net percent release offl-hexosaminidase and 35S-labeled proteoglycan (data from Figs. 
2 and 3)  yielded r =  0.77  (n -- 27, P  <  0.001), with the line intersecting they axis at 
a point not statistically different fgqm zero (Fig. 4)  (t =  0.75, P  >  0.05). 
Identification of Released asS-labeled Proteoglycan and Su~dopeptide  Leukotrienes.  Two sets 
of duplicate  samples of  1  ×  106  35S-labeled  bone  marrow-derived  mast  cells  were 
sensitized with  10/~g of IgE. The optimal concentration of antigen was added to one 
set while  the other set  remained  in buffer alone.  Both  sets were then  incubated  at 
37°C  for  10  min and  the cells sedimented by centrifugation.  100-#1 samples of the 
supernatants  from the stimulated cells, the extracts from the challenged cell pellets, 
and the extracts from the unchallenged cell pellets were chromatographed sequentially 
on Sepharose CL-4B. The asS-labeled proteoglycans from the unchallenged cells (Fig, 
5 A), from the challenged cells (Fig. 5 B), and from the supernatant of the challenged 
cells (Fig. 5 C) each filtered with an apparent 150,000-250,000 tool wt, which indicates 
that  the  hydrodynamic size of the proteoglycan was not  altered  during  the  release 
reaction. 
The asS-labeled proteoglycan from the cell extracts of unchallenged and challenged 
cells  and  from  the  supernatants  of challenged  cells  were  each  purified  by  cesium 
chloride density-gradient centrifugation and digested with chondroitinase ABC.  As- 
cending thin-layer chromatography revealed ultraviolet-absorbing products migrating 
at the positions of ADi-4S and ADi-6S, which is consistent with the reported mobility 
of the  digestion  products  of the  two  carrier  chondroitin  sulfates.  As  assessed  by 
autoradiography,  digestion  of the a~S-labeled proteoglycans  from the  unstimulated 
bone marrow-derived mast cells, from the stimulated cells, and from the supernatants 
of the stimulated cells yielded two products. These radiolabeled products migrated in 
the  positions  of ADi-4S  and  of an  oversulfated  disaccharide  previously  shown  to RAZIN  ET  AL.  195 
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Fzo.  5.  Sepharose CL-4B gel filtration, under dissociative conditions, of cell-associated ass-labeled 
proteogIycan in unchallenged cells (A)  and challenged cells (B)  and of [~S]proteoglycan released 
into  the supernatant  after antigen challenge  (C).  HP-PG, ass-labeled rat  heparin  proteoglycan, 
750,000  mol wt; HP, ass-labeled rat heparin glycosaminoglycan, 100,000  tool wt; DS, pig dermatan 
sulfate, 40,000  tool wt. Unlabeled markers were identified by determination of their uronic acid 
content. 
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FtG.  6.  Ascending thin-layer chromatography of chondroitinase ABC-treated 3~S-labeled  proteo- 
glycans from (A) unstimulated, sensitized bone marrow-derived mast cells, (B) antigen-challenged, 
sensitized, bone marrow-derived mast ceils, and (C) supernatant from antigen-challenged, sensitized, 
bone marrow-derived mast cells. The digestion products from the carrier glycosaminogl~cans and 
the  disaceharide  standards  were  visualized  by  ultraviolet  absorption,  whereas  the  aSS-labeled 
digestion products were detected by autoradiography. The radioactivity eluted from the chromat- 
ograms is indicated in parentheses in terms of percentage of distribution; recoveries were >95%. 
contain N-acetyl-galactosamine 4,6-disulfate, ADi-diSE (Fig. 6). Quantitation of the 
radiolabeled digestion products revealed two-thirds of the radioactivity to be associ- 
ated with the disulfated disaccharide, which indicates that the disulfated and mono- 
sulfated N-acetyl-galactosamines were equally present  in the undigested glycosami- 
noglycan,  as  previously observed  by analysis  of bot.h  radiolabeled  and  unlabeled 
chondroitin sulfate E  from the  resting mouse bone marrow-derived mast  cells  (9). 
Furthermore, the highly sulfated proteoglycan present in these mast cell granules did 
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FIG.  7.  RP-HPLC elution pattern ofimmunoreactive leukotrienes obtained from 1 X  106 sensitized 
bone marrow-derived mast cells subjected to antigen challenge for 0 (A), 1 (&),  2 (0), 5 (C)), and 30 
(0) rain at 37°C. 
To characterize the sulfidopeptide leukotriene products obtained at various times 
after antigen  challenge,  five duplicate  sets of sensitized  bone marrow-derived mast 
cells were challenged;  the supernatants were harvested at 0,  1, 2, 5, and 30 min and 
resolved by RP-HPLC. The recoveries after RP-HPLC were 73 and 76% of the total 
immunoreactive  material  applied  from  sensitized  cells  challenged  5  and  30  rain, 
respectively, with  antigen.  In each  experiment, >95%  of the  immunoreactive sulfi- 
dopeptide leukotrienes eluted at a  retention time of 15-16 rain  (Fig.  7), the same as 
that of authentic LTC4, which indicates that further processing to LTD4 and LTE4 
did  not  occur  within  this  time  period  after  antigen  challenge.  In  two  separate 
experiments involving duplicate sets of 1 ×  106 cells sensitized with IgE and challenged 
with the optimal concentration  of antigen  for  10 rain at 37°C,  the immunoreactive 
leukotrienes, which again eluted at  15-16 rain, had an average spasmogenic activity 
of 1.4  U/pmol in  assays in  which  synthetic  LTC4 had a  specific activity of 1.3  U/ 
pmol. 
Discussion 
Mouse bone marrow-derived mast cells respond to IgE-dependent activation with 
the release of the preformed mediators, histamine, fl-hexosaminidase, and chondroitin 
sulfate E proteoglycan and the generation and release of LTC4. The release of these 
mediators was related in a dose-dependent fashion to the concentration of monoclonal 
IgE used  during  the  sensitization  (Fig.  1)  and  to  the  concentration  of the  specific 
antigen used for activation (Fig. 2). The antigen-initiated response was not diminished 
by washing of the sensitized cells three times before antigen challenge. This indicated 
that the release of mediators involved the interaction of antigen with IgE fixed to the 
cell surface and not the phagocytosis of immune complexes formed in the fluid phase. 
The release of the preformed mediators,/~-hexosaminidase and 35S-labeled chondroitin 
sulfate E  proteoglycan, and of LTC4 followed similar kinetics beginning within 60 s 
after antigen  challenge  and  reaching plateaus  within  5  min  at  37°C  (Fig.  3).  The 
common  dose-response  relationships  observed  for  the  sensitizing  concentration  of 
monoclonal  IgE  and  for  the  quantity  of antigen  required  for  optimal  release  of 
preformed mediators and  of LTC4,  as  well  as  the  superimposable time courses  for RAZIN ET AL.  197 
their release, indicate  the origin of these  mediators  from a  common cell with  IgE 
receptors. 
As  assessed  by  histochemical  staining  for esterase-positive cells,  differential cell 
count after fixation and staining with Giemsa, and capacity to engage in a phagocytic 
response, <3%  of the cells in  the  14-d cultures of bone marrow-derived mast  cells 
could be defined as macrophage-like cells  (1).  Previous experiments indicated that 
these bone marrow-derived mast cell cultures produce -90 ng of LTC4/106 cells after 
calcium ionophore A23187 activation over a 40-min time period, with <18 ng being 
released by 5  rain  (11).  Whereas  the  ionophore-induced generation and  release of 
oxidative products of arachidonic acid do not define the nature of the responding cell 
in the culture, the release of preformed mediators and LTC4, after fixation of IgE and 
challenge of the cell with antigen,  unequivocally indicates a  bone marrow-derived 
mast cell origin for these molecules. 
The  release  of chondroitin  sulfate  E  proteoglycan was  not  accompanied  by  an 
apparent change in hydrodynamic size as assessed by gel filtration on Sepharose CL- 
4B  (Fig.  5).  That  the  released ~S-labeled macromolecules were indeed the unique 
chondroitin  sulfate  E  proteoglycan  (9)  was  established  by  the  digestion  of their 
radiolabeled side chains with chondroitinase ABC and identification of the disaccha- 
ride products containing approximately equal amounts of N-acetyl-galactosamine 4,6- 
disulfate and N-acetyl-galactosamine 4-sulfate (Fig. 6). Linear regression analysis of 
the relationship of net percent release of histamine to that offl-hexosaminidase yielded 
a  straight  line which intersected the origin.  Similarly, the statistical analysis of the 
relationship  of net  percent  release of fl-hexosaminidase to  35S-labeled chondroitin 
sulfate  E  proteoglycan yielded a  similar  regression  line  (Fig.  4).  These mediators, 
therefore, are localized in the secretory granules of the bone marrow-derived mast 
cells.  Similar  analysis  of mediator  release  data  has  previously  localized  heparin 
proteoglycan, neutral proteases (chymase and carboxypeptidase B), and acid hydro- 
lases (fl-hexosaminidase and fl-glucuronidase) to the secretory granules of rat perito- 
neal mast cells (7, 16). As the ratio of the net percent release of 35S-labeled chondroitin 
sulfate E  proteoglycan to fl-hexosaminidase of 0.75 is substantially greater than the 
ratio of net percent release of heparin to fl-hexosaminidase for rat  peritoneal mast 
cells (0.24), it is apparent that the 35S-labeled chondroitin sulfate E solubilizes from 
the  released  granule  much  more  readily  than  does  heparin.  Indeed,  even  when 
immunologically activated rat peritoneal mast  cells are washed with  1 M  NaC1 to 
solubilize the cell-associated proteoglycan and increase the release of heparin proteo- 
glycan, the release ratio rises to only 0.51 (16). Thus, whereas the heparin proteoglycan 
of" conventional mast  cells  forms an  insoluble complex with  the  neutral  proteases, 
which remains cell-associated even after the secretory granules have released soluble 
mediators  (such  as  fl-hexosaminidase  and  histamine),  the  chondroitin  sulfate  E 
proteoglycan of the bone marrow-derived mast cells is not substantially retarded in its 
diffusion  into  the  microenvironment.  The  localization  of ~S-labeled  chondroitin 
sulfate E  proteoglycan to the secretory granules and  the finding that  >90%  of the 
proteoglycan isolated from bone marrow-derived mast cells is chondroitin sulfate E 
(9) suggest that this proteoglycan is responsible for the characteristic metachromasia 
of the granule after staining with cationic dyes. 
Although it has long been recognized that  immediate-type hypersensitivity reac- 
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SRS-A, now known to be sulfidopeptide leukotrienes, the bone marrow-differentiated 
mouse mast cells are the first population of mast cells of >95% purity to consistently 
release large quantities  of LTC4 in  response to IgE antigen-specific activation.  The 
quantity  of immunoreactive leukotrienes  generated  by bone  marrow-derived  mast 
cells under optimal conditions of IgE-dependent sensitization and antigen challenge 
in nine separate experiments averaged 23 +  3 (mean _+ SEM) ng/106 cells.  The single 
immunoreactive  sulfidopeptide  leukotriene  generated  and  released  by  antigen-de- 
pendent  activation of IgE-sensitized bone marrow-derived mast cells was defined as 
LTC4 by its retention  time on  RP-HPLC  (Fig.  7)  and  by its biological activity on 
guinea pig ileum. The product was not converted to LTD4 or LTE4 within 30 min of 
its generation (Fig. 7). Previous studies demonstrated that bone marrow-derived mast 
cells also generated LTC4 upon activation with calcium ionophore A23187 and this 
product was not metabolized to either LTD4 or LTE4 within  1 h  of stimulation  (11). 
Thus,  the bone marrow-derived mast cells resemble zymosan-activated mouse peri- 
toneal or pulmonary interstitial macrophages (24,  25) and ionophore-activated mouse 
mastocytoma  (26)  in  not  processing  the  LTC4  that  they  generate.  This  finding 
contrasts with the ionophore-stimulated rat basophilic leukemia (RBL-I) cells, mouse 
pulmonary alveolar macrophages, and rat peritoneal mononuclear cells (25, 27, 28), 
which  generate  LTC4  and  then  convert  it  to  LTD4  in  a  time-dependent  fashion. 
Because  y-glutamyl  transpeptidase  is  likely  to  be  the  enzyme  responsible  for  this 
conversion (29), it is either absent or biologically unavailable in bone marrow-derived 
mast  cells  activated  to  release  LTC4  with  either  calcium  ionophore  or  an  IgE- 
dependent stimulus. 
The finding that bone marrow-derived mast cells generate LTC4 in approximately 
a  25:1  ratio to PGDz in response to either activation with the calcium ionophore (11) 
or perturbation of the IgE receptor contrasts with the finding that rat peritoneal mast 
cells respond to activation with a preferential generation of PGDe such that the ratio 
of LTC4 to PGD2 is < 1:40. This difference in the oxidative metabolism of arachidonic 
acid  in  response  to  immunologic  activation  of the  two  mast  cell  types  may have 
important biologic implications in view of recent findings of the differing pharmaco- 
logic actions of these two mediators on the vasculature of humans, guinea pigs, and 
hamsters  (30-32)  and  the  remarkable  potency  of  aerosolized  LTC4,  relative  to 
histamine in compromising pulmonary function of normal humans (33). 
Summary 
Mouse hone marrow-derived mast cells differentiated in vitro and sensitized with 
monoclonal IgE respond to antigen-initiated activation with the release of histamine, 
/?-hexosaminidase, chondroitin  sulfate  E  proteoglycan, and  leukotriene  C4  (LTC4). 
The chondroitin sulfate E nature of the glycosaminoglycan side chain was established 
by demonstrating that the chondroitinase ABC disaccharide digestion products were 
composed of equal quantities of 4-sulfated and 4,6-disulfated N-acetyl-galactosamine. 
The single immunoreactive sulfidopeptide leukotriene, released and quantitated with 
a class-specific antibody, was identified as LTC4 by its retention time on reverse-phase 
high-performance liquid chromatography and by its specific spasmogenic activity on 
the guinea pig ileum. The release of the preformed mediators, as well as of LTC4, was 
related in a dose-response fashion to the concentration of monoclonal IgE used during 
the sensitization step and to the concentration of specific antigen used to initiate the RAZIN ET  AL.  199 
activation-secretion response. The optimal concentrations of IgE for sensitization and 
of antigen for challenge were the same for the release of preformed mediators and of 
LTC4.  In  addition,  the  time  courses  of their  release  were  superimposable,  with  a 
plateau  at 5  min after antigen challenge. The release of three preformed mediators 
and  of  LTC4  after  fixation  of  IgE,  washing  of  the  sensitized  cells,  and  antigen 
challenge unequivocally indicates a  bone  marrow-derived mast  cell origin  for these 
products. Linear regression analyses of the net percent release of,&hexosaminidase to 
histamine and of a~S-chondroitin sulfate E  to/~-hexosaminidase yielded straight lines 
that intersected at the origin, which indicates that the three preformed mediators are 
localized  in  the  secretory  granules  of  the  bone  marrow-derived  mast  cells.  The 
concomitant  generation of 23 ng of LTC4/10 e sensitized bone marrow-derived mast 
cells represents the first example of IgE-dependent release of substantial amounts of 
LTC4,  a  component  of slow  reacting  substance  of anaphylaxis,  from  a  mast  cell 
population  of >95%  purity.  The  IgE-dependent  generation  of LTC4,  rather  than 
prostaglandin D2, by the chondroitin sulfate E proteoglycan-containing bone marrow- 
derived mast cells contrasts with the predominant generation of prostaglandin D2 by 
heparin  proteoglycan-containing mast  cells. These  differences together support  the 
existence of two phenotypically different mast cell subclasses. 
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